Roger Adami
Chief Technology Officer Land Therapeutics
Roger Adami, Ph.D. is Chief Technology Officer at Land Therapeutics Inc., where he leads the development of in vivo targeted gene editing drugs to treat genetic diseases with precision and innovation. With over two decades of experience in pharmaceutical R&D, Dr. Adami brings deep expertise in drug delivery, formulation, and platform development.
Previously, he served as VP of Pharmaceutical Sciences and Business Development at Nitto BioPharma Inc., where he led the creation of novel lipid nanoparticle systems for RNA delivery. His leadership spanned chemistry, formulation, analytics, and manufacturing, while also driving strategic partnerships and external collaborations.
Dr. Adami began his career at Pfizer Inc. and held leadership roles at Marina Biotech and Permesys, a personalized medicine startup he founded. He holds a Ph.D. in Pharmaceutics from the University of Michigan, and degrees in Chemical Engineering and Biochemistry from the University of Illinois, Chicago.
Seminars
- Tackling common safety challenges of LNPs to enable redosability for more effective therapies
- Discussing the causes and impact of batch-to-batch variability and gaining insights into practical approaches for improving consistency
- Evaluating best practices for improving LNP stability and formulation to ensure global availability
- Diving into the fundamentals of targeted LNP design, including ligand selection and surface modifications
- Reviewing the biological and formulation factors that influence tissue and cell specificity
- Analyzing current applications and early strategies used to enhance precision and reduce off-target effects
NEW COMPANY
